Shree Ganesh Remedies credit ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024

30.7	38.2	36.3
4.8	10.0	15.5
0.19×	0.26×	0.30×
0.03×	0.07×	0.13×
0.88×	0.98×	0.87×
0.14×	0.25×	0.37×
6.89×	14.27×	59.75×
15.8%	20.8%	22.9%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

SGRL₹639.75

Shree Ganesh Remedies Limited

· Pharma & Health

₹ CrorePeersBPLPHARMA JENBURPH KPL MAKERSL NOVARTIND PARNAXLAB SHUKRAPHAR SUNLOCMcap ₹822 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026
Total Debt	36.3	38.2	30.7
Net Debt	15.5	10.0	4.8
Total Debt/Equity	0.30	0.26	0.19
Net Debt/Equity	0.13	0.07	0.03
Total Debt/EBITDA	0.87	0.98	0.88
Net Debt/EBITDA	0.37	0.25	0.14
Interest Coverage (EBIT/Interest)	59.75	14.27	6.89
Total Debt/Total Capital %	22.92	20.85	15.84

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.